Cost-effectiveness of alternative strategies for integrating MRI into breast cancer screening for women at high risk

British Journal of Cancer

Volumn 111, Issue 8, 2014, Pages 1542-1551

  Ahern, C H ^a   Shih, Y C T ^b   Dong, W ^c   Parmigiani, G ^d,e   Shen, Y ^c  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF CHICAGO   (United States)

^c UNIVERSITY OF TEXAS   (United States)

^d DANA FARBER CANCER INSTITUTE   (United States)

^e HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; BREAST NEOPLASMS; COST BENEFIT ANALYSIS; ECONOMICS; FEMALE; HUMAN; MASS SCREENING; MIDDLE AGED; MONTE CARLO METHOD; NUCLEAR MAGNETIC RESONANCE IMAGING; RISK FACTOR; UTILIZATION;

ADULT; BREAST NEOPLASMS; COST-BENEFIT ANALYSIS; FEMALE; HUMANS; MAGNETIC RESONANCE IMAGING; MASS SCREENING; MIDDLE AGED; MONTE CARLO METHOD; RISK FACTORS;

EID: 84908889251     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2014.458     Document Type: Article

References (59)

1. Afonso NM (2009) Women at high risk for breast cancer-what the primary care provider needs to know. J Am Board Fam Med 22: 43-50.
2. Ahern CH, Shen Y (2009) Cost-effectiveness analysis of mammography and clinical breast examination strategies: a comparison with current guidelines. Cancer Epidemiol Biomarkers Prev 18(3): 718-725.
3. Allen JM (2010) Economic/societal burden of metastatic breast cancer: a US perspective. Am J Manag Care 16(9): 697-704.
4. American Cancer Society: Detailed Guide: breast cancer. Can breast cancer be found early? http://www.cancer.org/docroot/CRI/content/ CRI-2-4-3X-Can-breast-cancer-be-found-early-5.asp.
5. Antoniou A, Pharoah PD, Narod S, Risch HA, Eyfjord JE, Hopper JL, Loman N, Olsson H, Johannsson O, Borg A, Pasini B, Radice P, Manoukian S, Eccles DM, Tang N, Olah E, Anton-Culver H, Warner E, Lubinski J, Gronwald J, Gorski B, Tulinius H, Thorlacius S, Eerola H, Nevanlinna H, Syrjakoski K, Kallioniemi OP, Thompson D, Evans C, Peto J, Lalloo F, Evans DG, Easton DF (2003) Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet 72(5): 1117-1130.
6. Barlow WE, Taplin SH, Yoshida CK, Buist DS, Seger D, Brown M (2001) Cost comparison of mastectomy versus breast-conserving therapy for early-stage breast cancer. J Natl Cancer Inst 93(6): 447-455.
7. Barlow WE, White E, Ballard-Barbash R, Vacek PM, Titus-Ernstoff L, Carney PA, Tice JA, Buist DS, Geller BM, Rosenberg R, Yankaskas BC, Kerlikowske K (2006) Prospective breast cancer risk prediction model for women undergoing screening mammography. J Natl Cancer Inst 98(17): 1204-1214.
8. Bureau of Labor Statistics: Consumer Price Index. http://data.bls.gov/CPI/.
9. Centers for Disease Control and Prevention: Breast cancer statistics. http:// www.cdc.gov/cancer/breast/statistics/.
10. Centers for Medicare and Medicaid Services (2012) 2012 National physician fee schedule relative value file. http://cms.gov/Medicare/Medicare-Fee-for-Service-Payment/PhysicianFeeSched/PFS-Relative-Value-Files.htmlAccessed 27 January 2014.
11. Chavez-MacGregor M, Zhang N, Buchholz TA, Zhang Y, Niu J, Elting L, Smith BD, Hortobagyi GN, Giordano SH (2013) Trastuzumab-related cardiotoxicity among older patients with breast cancer. J Clin Oncol 31(33): 4222-4228.
12. Chen TH, Kuo HS, Yen MF, Lai MS, Tabar L, Duffy SW (2000) Estimation of sojourn time in chronic disease screening without data on interval cases. Biometrics 56(1): 167-172.
13. ClinicalTrials.gov: A service of the U.S. National Institutes of Health. http:// clinicaltrials.gov/ct2/results?term=BreastMRIHighRisk.
14. Cott Chubiz JE, Lee JM, Gilmore ME, Kong CY, Lowry KP, Halpern EF, McMahon PM, Ryan PD, Gazelle GS (2013) Cost-effectiveness of alternating magnetic resonance imaging and digital mammography screening in BRCA1 and BRCA2 gene mutation carriers. Cancer 119(6): 1266-1276.
15. Cummings SR, Tice JA, Bauer S, Browner WS, Cuzick J, Ziv E, Vogel V, Shepherd J, Vachon C, Smith-Bindman R, Kerlikowske K (2009) Prevention of breast cancer in postmenopausal women: approaches to estimating and reducing risk. J Natl Cancer Inst 101(6): 384-398.
16. Dahabreh IJ, Linardou H, Siannis F, Fountzilas G, Murray S (2008) Trastuzumab in the adjuvant treatment of early-stage breast cancer: a systematic review and meta-analysis of randomized controlled trials. Oncologist 13(6): 620-630.
17. Day JC, Newburger EC (2002) The big payoff: educational attainments and synthetic estimates of work-life earnings, 2002. http://www.census.gov/ prod/2002pubs/p23-210.pdf.
18. de Bock GH, Vermeulen KM, Jansen L, Oosterwijk JC, Siesling S, Dorrius MD, Feenstra T, Houssami N, Greuter MJ (2013) Which screening strategy should be offered to women with BRCA1 or BRCA2 mutations? A simulation of comparative cost-effectiveness. Br J Cancer 108(8): 1579-1586.
19. Elmore JG, Armstrong K, Lehman CD, Fletcher SW (2005) Screening for breast cancer. JAMA 293(10): 1245-1256.
20. Fisher B, Costantino JP,Wickerham DL, Redmond CK, Kavanah M, Cronin WM, Vogel V, Robidoux A, Dimitrov N, Atkins J, Daly M,Wieand S, Tan-Chiu E, Ford L, Wolmark N (1998) Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 90(18): 1371-1388.
21. Heijnsdijk EA, Warner E, Gilbert FJ, Tilanus-Linthorst MM, Evans G, Causer PA, Eeles RA, Kaas R, Draisma G, Ramsay EA, Warren RM, Hill KA, Hoogerbrugge N, Wasser MN, Bergers E, Oosterwijk JC, Hooning MJ, Rutgers EJ, Klijn JG, Plewes DB, Leach MO, de Koning HJ (2012) Differences in natural history between breast cancers in BRCA1 and BRCA2 mutation carriers and effects of MRI screening-MRISC, MARIBS, and Canadian studies combined. Cancer Epidemiol Biomarkers Prev 21(9): 1458-1468.
22. Hunink M, Glasziou P, Siegel J, Weeks J, Pilskin J, Elstein A, Weinstein M (2001) Decision Making in Health and Medicine: Integrating Evidence and Values. Cambridge University Press: New York, NY.
23. Kerlikowske K, Carney PA, Geller B, Mandelson MT, Taplin SH, Malvin K, Ernster V, Urban N, Cutter G, Rosenberg R, Ballard-Barbash R (2000) Performance of screening mammography among women with and without a first-degree relative with breast cancer. Ann Intern Med 133(11): 855-863.
24. Kriege M, Brekelmans CT, Boetes C, Besnard PE, Zonderland HM, Obdeijn IM, Manoliu RA, Kok T, Peterse H, Tilanus-Linthorst MM, Muller SH, Meijer S, Oosterwijk JC, Beex LV, Tollenaar RA, de Koning HJ, Rutgers EJ, Klijn JG (2004) Efficacy of MRI and mammography for breast-cancer screening in women with a familial or genetic predisposition. N Engl J Med 351(5): 427-437.
25. Kriege M, Brekelmans CT, Obdeijn IM, Boetes C, Zonderland HM, Muller SH, Kok T, Manoliu RA, Besnard AP, Tilanus-Linthorst MM, Seynaeve C, Bartels CC, Kaas R, Meijer S, Oosterwijk JC, Hoogerbrugge N, Tollenaar RA, Rutgers EJ, de Koning HJ, Klijn JG (2006) Factors affecting sensitivity and specificity of screening mammography and MRI in women with an inherited risk for breast cancer. Breast Cancer Res Treat 100(1): 109-119.
26. Kuhl CK, Schrading S, Leutner CC, Morakkabati N, Trog D, Schmutzler R, Schild HH (2003) Surveillance of ''high risk'' women with proven or suspected familial (hereditary) breast cancer: first mid-term results of a multi-modality clinical screening trial. Proc Am Soc Clin Oncol 22: 2.
27. Leach MO, Boggis CR, Dixon AK, Easton DF, Eeles RA, Evans DG, Gilbert FJ, Griebsch I, Hoff RJ, Kessar P, Lakhani SR,Moss SM, Nerurkar A, Padhani AR, Pointon LJ, Thompson D, Warren RM (2005) Screening with magnetic resonance imaging and mammography of a UK population at high familial risk of breast cancer: a prospective multicentre cohort study (MARIBS). Lancet 365(9473): 1769-1778.
28. Mariotto AB, Feuer EJ, Harlan LC, Abrams J (2006) Dissemination of adjuvant multiagent chemotherapy and tamoxifen for breast cancer in the United States using estrogen receptor information: 1975-1999. J Natl Cancer Inst Monogr 36: 7-15.
29. Moore SG, Shenoy PJ, Fanucchi L, Tumeh JW, Flowers CR (2009) Cost-effectiveness of MRI compared to mammography for breast cancer screening in a high risk population. BMC Health Serv Res 9: 9.
30. National Cancer Institute: Breast Cancer Surveillance Consortium. http://breastscreening.cancer.gov/data/benchmarks/diagnostic/ tableSensSpec.html.
31. NIH Consensus Statement (2000) Adjuvant therapy for breast cancer 17(4): 1-23.
32. Parmigiani G (1993) On optimal screening ages. J Am Stat Assoc 88(422): 622-628.
33. Parmigiani G (2002) Modeling in Medical Decision Making. John Wiley and Sons, Ltd: West Sussex, England.
34. Pataky R, Armstrong L, Chia S, Coldman AJ, Kim-Sing C, McGillivray B, Scott J, Wilson CM, Peacock S (2013) Cost-effectiveness of MRI for breast cancer screening in BRCA1/2 mutation carriers. BMC Cancer 13: 339.
35. Perloff M, Norton L, Korzun AH, Wood WC, Carey RW, Gottlieb A, Aust JC, Bank A, Silver RT, Saleh F, Canellos GP, Perry MC, Weiss RB, Holland JF (1996) Postsurgical adjuvant chemotherapy of stage II breast carcinoma with or without crossover to a non-cross-resistant regimen: a Cancer and Leukemia Group B study. J Clin Oncol 14(5): 1589-1598.
36. Petitti D (2000) Meta-analysis, Decision Analysis, and Cost-effectiveness Analysis. II edn. Oxford University Press, Inc.: New York, NY.
37. Plevritis SK, Kurian AW, Sigal BM, Daniel BL, Ikeda DM, Stockdale FE, Garber AM (2006) Cost-effectiveness of screening BRCA1/2 mutation carriers with breast magnetic resonance imaging. JAMA 295(20): 2374-2384.
38. Ries LAG, Eisner MP, Kosary CL, Hankey BA, Clegg L, Mariotto A, Feuer EJ, Edwards BK (2005) SEER Cancer Statistics Review, 1975-2002. National Cancer Institute: Bethesda, MDhttp://seer.cancer.gov/csr/1975-2002/ based on November 2004 SEER data submission, posted to the SEER web site 2005.
39. Rijnsburger AJ, Obdeijn IM, Kaas R, Tilanus-Linthorst MM, Boetes C, Loo CE, Wasser MN, Bergers E, Kok T, Muller SH, Peterse H, Tollenaar RA, Hoogerbrugge N, Meijer S, Bartels CC, Seynaeve C, Hooning MJ, Kriege M, Schmitz PI, Oosterwijk JC, de Koning HJ, Rutgers EJ, Klijn JG (2010) BRCA1-associated breast cancers present differently from BRCA2-associated and familial cases: long-term follow-up of the Dutch MRISC Screening Study. J Clin Oncol 28(36): 5265-5273.
40. Riley GF, Lubitz JD (2010) Long-term trends in Medicare payments in the last year of life. Health Serv Res 45(2): 565-576.
41. Saadatmand S, Tilanus-Linthorst MM, Rutgers EJ, Hoogerbrugge N, Oosterwijk JC, Tollenaar RA, Hooning M, Loo CE, Obdeijn IM, Heijnsdijk EA, de Koning HJ (2013) Cost-effectiveness of screening women with familial risk for breast cancer with magnetic resonance imaging. J Natl Cancer Inst 105(17): 1314-1321.
42. Saslow D, Boetes C, Burke W, Harms S, Leach MO, Lehman CD, Morris E, Pisano E, Schnall M, Sener S, Smith RA, Warner E, Yaffe M, Andrews KS, Russell CA (2007) American Cancer Society guidelines for breast screening with MRI as an adjunct to mammography. CA Cancer J Clin 57(2): 75-89.
43. Shen Y, Dong W, Esteva FJ, Kau SW, Theriault RL, Bevers TB (2007) Are there racial differences in breast cancer treatments and clinical outcomes for women treated at M.D. Anderson Cancer Center? Breast Cancer Res Treat 102(3): 347-356.
44. Shen Y, Parmigiani G (2005) A model-based comparison of breast cancer screening strategies: mammograms and clinical breast examinations. Cancer Epidemiol Biomarkers Prev 14(2): 529-532.
45. Shen Y, Parmigiani G (2006) Optimization of breast cancer screening modalities. In Probability, Statistics, and Modelling in Public Health, Nikoulina M, Commenges D, Huber C (eds), pp 405-420. Springer Business Media, Inc.: USA.
46. Shen Y, Wu D, Zelen M (2001) Testing the independence of two diagnostic tests. Biometrics 57(4): 1009-1017.
47. Shih YC, Elting LS, Pavluck AL, Stewart A, Halpern MT (2010) Immunotherapy in the initial treatment of newly diagnosed cancer patients: utilization trend and cost projections for non-Hodgkin's lymphoma, metastatic breast cancer, and metastatic colorectal cancer. Cancer Invest 28(1): 46-53.
48. Singletary SE, Allred C, Ashley P, Bassett LW, Berry D, Bland KI, Borgen PI, Clark G, Edge SB, Hayes DF, Hughes LL, Hutter RV, Morrow M, Page DL, Recht A, Theriault RL, Thor A, Weaver DL, Wieand HS, Greene FL (2002) Revision of the American Joint Committee on Cancer staging system for breast cancer. J Clin Oncol 20(17): 3628-3636.
49. Smith RA, Saslow D, Sawyer KA, Burke W, Costanza ME, Evans III WP, Foster Jr RS, Hendrick E, Eyre HJ, Sener S (2003) American Cancer Society guidelines for breast cancer screening: update 2003. CA Cancer J Clin 53(3): 141-169.
50. Taneja C, Edelsberg J, Weycker D, Guo A, Oster G, Weinreb J (2009) Cost effectiveness of breast cancer screening with contrast-enhanced MRI in high-risk women. J Am Coll Radiol 6(3): 171-179.
51. Tengs TO, Wallace A (2000) One thousand health-related quality-of-life estimates. Med Care 38(6): 583-637.
52. Tilanus-Linthorst MM, Obdeijn IM, Hop WC, Causer PA, Leach MO, Warner E, Pointon L, Hill K, Klijn JG, Warren RM, Gilbert FJ (2007) BRCA1 mutation and young age predict fast breast cancer growth in the Dutch, United Kingdom, and Canadian magnetic resonance imaging screening trials. Clin Cancer Res 13(24): 7357-7362.
53. Ubel PA, Hirth RA, Chernew ME, Fendrick AM (2003) What is the price of life and why doesn't it increase at the rate of inflation? Arch Intern Med 163(14): 1637-1641.
54. UK CR (2012) Who is screened for breast cancer? Vol. 2014.
55. Warner E, Plewes DB, Hill KA, Causer PA, Zubovits JT, Jong RA, Cutrara MR, DeBoer G, Yaffe MJ, Messner SJ, Meschino WS, Piron CA, Narod SA (2004) Surveillance of BRCA1 and BRCA2 mutation carriers with magnetic resonance imaging, ultrasound, mammography, and clinical breast examination. JAMA 292(11): 1317-1325.
56. Weedon-Fekjar H, Lindqvist BH, Vatten LJ, Aalen OO, Tretl S (2008) Breast cancer tumor growth estimated through mammography screening data. Breast Cancer Res 10(3): R41.
57. Wood WC, Budman DR, Korzun AH, Cooper MR, Younger J, Hart RD, Moore A, Ellerton JA, Norton L, Ferree CR (1994) Dose and dose intensity of adjuvant chemotherapy for stage II, node-positive breast carcinoma. N Engl J Med 330(18): 1253-1259.
58. Wood WC, Weiss RB, Tormey DC, Holland JF, Henry PH, Leone LA, Rafla S, Silver RT, Carey RW, Lesnick GJ (1985) A randomized trial of CMF versus CMFVP as adjuvant chemotherapy in women with node-positive stage II breast cancer: a CALGB Study. World J Surg 9(5): 714-718.
59. Yabroff KR, Lamont EB, Mariotto A, Warren JL, Topor M, Meekins A, Brown ML (2008) Cost of care for elderly cancer patients in the United States. J Natl Cancer Inst 100(9): 630-641.